# Taxotere + Cisplatin in Nasopharyngeal Carcinoma

> **NCT00436293** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 61 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00436293
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2010-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436293, "Taxotere + Cisplatin in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00436293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*